Skip to content

Compression Stockings for Lymphedema Prevention in Gynecologic Cancer Patients

Compression Stockings for Preventing Lower Limb Lymphedema in Women Treated for Gynecological Malignancies

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06873984
Acronym
csplwgm
Enrollment
60
Registered
2025-03-13
Start date
2016-12-01
Completion date
2020-12-20
Last updated
2025-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphedema

Keywords

Lower limb lympodema, compression therapy, quality of life

Brief summary

The goal of this clinical trial was to evaluate whether compression stockings (23-32 mmHg) reduce the incidence of postoperative lymphedema and accompanying symptoms, as well as to assess the comfort of using compression in women undergoing treatment for gynecological malignancies up to one year after surgery. The main objectives were to determine: Whether compression stockings applied immediately after radical surgery, in combination with physical activity, reduce the risk of developing lymphedema. Whether the use of compression stockings affects the quality of life. Whether compression stockings influence specific physical complaints related to the lower limbs. Patients were assessed preoperatively and at 3, 6, and 12 months postoperatively. Limb circumferences were measured at predefined anatomical points to calculate limb volume changes over time. Additionally, subjective symptoms, quality of life, and adherence to compression therapy were evaluated. Researchers compared a group using compression stockings with a control group without compression to analyze potential benefits and complications.

Detailed description

Background and Rationale Lymphedema is a frequent and debilitating complication following radical surgery for gynecological malignancies. It affects patients' quality of life, contributing to discomfort, impaired mobility, and an increased risk of infections. Despite the widespread use of compression therapy in managing lymphedema, there is limited evidence on its preventive role when applied immediately after surgery. This study investigates the effectiveness of compression stockings (23-32 mmHg) in reducing the incidence of postoperative lower limb lymphedema and associated symptoms in women undergoing treatment for gynecological cancers. Additionally, it evaluates the impact of compression on patients' quality of life and physical complaints up to one year postoperatively. A total of 75 eligible women consented to participate and were preoperatively randomized (simple randomization using a random number generator) into two groups: Compression Group (CG): Patients received individually fitted round-knit compression stockings (23-32 mmHg, RAL-GZG standard) and were instructed to wear them for approximately 9 hours per day. No Compression Group (NCG): Patients did not receive compression therapy. Descriptive statistics were used to summarize the collected data, including mean (x̄), standard deviation (SD), median (Me), and percentage distributions. For sociodemographic and clinical data, comparisons between groups were performed using the chi-square test for categorical variables and the independent t-test for continuous variables. The effects of physiotherapeutic interventions were analyzed to determine statistically significant differences between groups. To assess the normality of data distribution, the Shapiro-Wilk test was applied. For quantitative variables related to limb volume and WAC (Water-Assisted Circumference), comparisons between two groups were conducted using the Mann-Whitney U test. Comparisons of quantitative variables across three or more groups were performed using the Kruskal-Wallis test, followed by Dunn's post-hoc test when significant differences were detected. Correlations between quantitative variables (e.g., limb volume and WAC) were assessed using Spearman's correlation coefficient. For repeated measurements of quantitative variables (e.g., limb volume and WAC at multiple time points), comparisons were conducted using the Friedman test, and when significant differences were found, Wilcoxon signed-rank tests with Bonferroni correction were used for post-hoc analysis. Qualitative variables were analyzed by calculating the number and percentage of occurrences for each category. Comparisons of categorical variables between groups were performed using the chi-square test (with Yates' correction for 2x2 tables) or Fisher's exact test for small expected frequencies. For comparisons of continuous variables across two time points, the Wilcoxon signed-rank test for paired samples was used. A significance level of p \< 0.05 was adopted, and all p-values below this threshold were considered statistically significant.

Interventions

OTHERcompression products

Compression Group (CG): Participants received individually fitted, round-knit compression stockings with a pressure of 23-32 mmHg (Class 2, RAL-GZG standard). Compression garments were selected based on circumference measurements taken in the morning to ensure proper fit. Participants were instructed to wear the stockings for approximately 9 hours per day. The compression garments were provided by the same manufacturer (Medi GmbH & Co., Bayreuth, Germany). Additionally, participants were advised to engage in daily physical activity (walking for at least 20 minutes per day) while wearing compression. Comprehensive education was provided on skin care, self-manual lymph drainage (simple lymph drainage, SLD), and lymphedema prevention.

Sponsors

Joanna Kurpiewska-Pieniążek
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Women who underwent radical surgery for vulvar cancer. Women who underwent radical surgery for cervical, uterine, or ovarian cancer, with systemic pelvic lymph node dissection. Overweight or obese patients (BMI \> 25.0 kg/m²) treated for uterine or ovarian cancer, regardless of whether systemic pelvic lymph node dissection was performed. Women over 18 years of age.

Exclusion criteria

Women with a history of lymphedema, venous edema, an ECOG score \> 2, congestive heart failure, renal failure, hypothyroidism, leg ulcers, or severe lower limb ischemia (Fontaine class ≥ 2), as well as those with metastases, relapse, or other malignancies treated within five years prior to study entry, were excluded.

Design outcomes

Primary

MeasureTime frameDescription
Change in Lower Limb Volume (%)Measurements were taken preoperatively and at 3, 6, and 12 months postoperativelyLower limb volume change (%) was calculated based on circumferential measurements taken every 4 cm along the limb, using the truncated cone formula. . The percentage change was calculated relative to preoperative limb volume. Unit of Measure: Percentage (%)

Secondary

MeasureTime frameDescription
Presence of Lymphedemawere noted before and after 3, 6 and 12 months after surgeryDescription: Lymphedema was diagnosed if limb volume increased by ≥10% compared to the contralateral limb or if skin stiffness appeared with a ≥8% volume difference. Unit of Measure: Number of participants with lymphedema
Relative Edema Size (%)were taken before and after 3, 6 and 12 months after surgery iIf edema occurred, its relative size (%) was calculated as the volume difference between the affected and healthy limb, expressed as a percentage of the healthy limb's volume. Unit of Measure: Percentage (%)
Weight-Adjusted Volume Change (WAC) (%)were taken before and after 3, 6 and 12 months after surgeryTo account for body weight fluctuations, limb volume was normalized using the WAC formula: WAC = (A2 \* W1) / (W2 \* A1) - 1 where A1 and A2 were pre- and postoperative limb volumes, and W1 and W2 were pre- and postoperative body weights. Unit of Measure: Percentage (%)

Other

MeasureTime frameDescription
The assessment of compression compliance12 months postoperativelywas based on the International Compression Questionnaire (ICC) taking into account the functional condition of women before starting to use compression and the evaluation of the tested compression stockings after 12 months in CG group. The severity of physical conditions reported before beginning to use compression was presented on a numeric rating scale (NRS) from 0 to 10, where 0 denoted no symptoms and 10 stood for a very high severity of a given symptom. Compression comfort (easy donning; easy doffing; feeling immediately after donning; feeling during daytime; putting on clothes on compression; the appearance of the garment (NRS: 0 = not able at all, 10 = completely able, sum of points) and complications of compression related to skin irritation, tender, spots. skin damage, itching, warmth, throbbing, cramps, cutting in, slippage, local swelling, bulky feeling, and too-tight feeling (NRS: 0 = not present at all, 10 = very obviously present
Quality of Life (EORTC QLQ-C30 Score)Assessments were conducted at 12 months postoperativelyQuality of life was assessed using the standardized EORTC QLQ-C30 (version 3.0) questionnaire for cancer patients. It included five functional scales (physical, role, emotional, cognitive, and social functioning), three symptom scales (fatigue, nausea/vomiting, pain), six single-item symptom questions (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties), and two global health status questions. Scores were analyzed according to EORTC scoring guidelines. Unit of Measure: EORTC QLQ-C30 score (0-100)
Physical Symptoms Related to Lower Limb LymphedemaSymptoms were recorded before surgery and at 3, 6, and 12 months postoperatively.The frequency of six physical symptoms associated with lower limb lymphedema (pain, limb heaviness, skin tightness, numbness, genital swelling, and lymph leakage) was assessed using a custom Likert-type scale (0 = never, 1 = sometimes, 2 = often, 3 = very often, 4 = all the time). Participants rated these symptoms preoperatively and at 3, 6, and 12 months post-treatment. Unit of Measure: Likert scale score (0-4)

Countries

Poland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026